News | Proton Therapy | May 25, 2018

More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage

Alliance for Proton Therapy Access launches grassroots campaign calling for state insurance commissioners to fix insurance process

More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage

May 25, 2018 — The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial burden that many cancer patients endure when trying to get their insurer’s approval for physician-recommended proton radiation therapy. The report – Cancer Care Denied: The Broken State of Patient Access to Proton Therapy – calls on insurance commissioners in all 50 states to adopt and enforce the principles of a Cancer Patients’ Timely Treatment Bill of Rights and hold insurers accountable for providing fair, timely and transparent access to cancer treatment.

According to patient data provided by several proton therapy centers, nearly two-thirds (63 percent) of cancer patients aged 18 to 64 whose physicians recommend proton therapy as the best course of treatment for their disease are initially denied by their insurer. The report reveals that patients and their physicians are sometimes successful in reversing the initial denial, but time spent waiting – and delaying treatment – averages nearly three weeks (13 working days). In the end, proton therapy is denied more than four times out of ten (42 percent) and it takes an average of more than five weeks (27 working days) to receive that final denial.

“When dealing with the enormity of a cancer diagnosis, private health insurers are adding undue physical, emotional and financial stress on patients. They are denying payment, dragging patients, their families and their doctors through lengthy appeals processes, and delaying access to treatment — seemingly in a systematic and intentional manner,” said Daniel E. Smith, executive director of the alliance. “Unfortunately, delay and deny is a common practice for insurers, signaling an urgent need for solutions that hold them accountable.”

The alliance is launching Cancer Care Denied, a grassroots campaign to shift the balance of power and give physicians and patients more say in cancer care. They are calling on insurance commissioners in all 50 states to adopt and enforce principles of a Cancer Patients’ Timely Treatment Bill of Rights. The Bill of Rights calls for:

  • Fair, timely and appropriate access to doctor-recommended cancer treatment;
  • Enforcement mechanisms executed by insurance commissioners, including automatic approvals if insurers fail to meet timelines and meaningful fines for repeated failure to provide fair, appropriate approvals; and
  • The same rights for cancer patients covered by employer self-funded plans.

The failure of insurers to abide by these simple principles imposes tremendous physical and financial stress on patients, according to the alliance. The alliance’s report includes detailed accounts from a number of cancer patients affected by the disproportionate power wielded by health insurers over patients and their physicians, including: 

“By adopting and enforcing common-sense principles, state insurance commissioners can take an important step toward repairing the broken system cancer patients face when they and their doctors are fighting for the best chance at survival and the highest quality of life,” added Smith. “Cancer patients should be fighting cancer, not their insurance companies.”

Proton therapy is a U.S. Food and Drug Administration (FDA)-cleared treatment, often approved for pediatric and Medicare patients, that allows physicians to precisely control and conform the bulk of its cancer-fighting proton energy field on cancerous cells. This minimizes extraneous radiation dose to healthy tissues, preserving organ function and potentially reducing harmful side effects. Proton therapy is medically necessary for many patients suffering from a variety of cancers.

For more information: www.allianceforprotontherapy.org

Related Content

Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...